Piramal Pharma Share Price
212.45-2.04 (-0.95%)
+5.61% past 1 Year
Piramal Pharma (PPL) is one of the India’s largest Pharmaceutical Company. PPL offers a portfolio of differentiated products and services through its global development and manufacturing facilities and a global
Corporate filings & documents
Announcements
Please refer attached file
23 hours agoPlease refer attached file
23 hours agoThe Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations 2011 for Deutsche Bank AG
1 week agoThe Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations 2011 for Deutsche Bank AG
1 week agoPlease refer attached file
1 week agoPlease refer attached file
1 week agoPlease find enclosed intimation of acquisition of additional stake in Yapan Bio Private Limited
2 weeks agoPlease find enclosed intimation of acquisition of additional stake in Yapan Bio Private Limited
2 weeks agoThe Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations 2011 for Deutsche Bank AG
2 weeks agoThe Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations 2011 for Deutsche Bank AG
2 weeks agoPlease find enclosed intimation of exercise of call option for acquisition of additional equity stake in Yapan Bio Private Limited
3 weeks agoPlease find enclosed intimation of exercise of call option for acquisition of additional equity stake in Yapan Bio Private Limited
3 weeks agoIntimation of Schedule of Analyst/ Institutional Investor Meetings under the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015
3 weeks agoIntimation of Schedule of Analyst/ Institutional Investor Meetings under the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015
3 weeks agoPlease refer attachment
1 month agoPlease refer attachment
1 month agoPlease find enclosed details of Earning call Transcript held on 30th July 2026.
1 month agoPlease find enclosed details of Earning call Transcript held on 30th July 2026.
1 month agoReport of the Scrutinizer along with the voting results of the businesses transacted at the AGM
1 month agoReport of the Scrutinizer along with the voting results of the businesses transacted at the AGM
1 month agoProceedings and Voting Results of the 6th Annual General Meeting of the Company
1 month agoProceedings and Voting Results of the 6th Annual General Meeting of the Company
1 month agoPlease find enclosed intimation of audio recordings of the conference call held today 30th July 2026.
1 month agoPlease find enclosed intimation of audio recordings of the conference call held today 30th July 2026.
1 month agoPlease see enclosed Investor Presentation for Q1 FY 27
1 month agoPlease see enclosed Investor Presentation for Q1 FY 27
1 month agoPlease see enlcosed Press Release for Q1 FY 27
1 month agoPlease see enlcosed Press Release for Q1 FY 27
1 month agoPlease find enlcosed UFR Q1 FY 27.
1 month agoPlease find enlcosed UFR Q1 FY 27.
1 month agoPlease find enclosed outcome of Board Meeting of Piramal Pharma Limited held on 29th July 2026
1 month agoPlease find enclosed outcome of Board Meeting of Piramal Pharma Limited held on 29th July 2026
1 month agoGrant of Stock Options pursuant to Piramal Pharma Limited - Employee Stock Option and Incentive Plan 2022
1 month agoGrant of Stock Options pursuant to Piramal Pharma Limited - Employee Stock Option and Incentive Plan 2022
1 month agoPlease refer attachment.
1 month agoPlease refer attachment.
1 month agoPlease find enclosed intimation of Analyst Meet scheduled to be held on 30th July 2026.
1 month agoPlease find enclosed intimation of Analyst Meet scheduled to be held on 30th July 2026.
1 month agoPiramal Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 29/07/2026 inter alia to consider and approve the Unaudited Financial Results (Standalone and Consolidated) of the Company for quarter ended 30th June 2026.
1 month agoPiramal Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 29/07/2026 inter alia to consider and approve the Unaudited Financial Results (Standalone and Consolidated) of the Company for quarter ended 30th June 2026.
1 month agoThe Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations 2011 for HDFC Mutual Fund
1 month agoThe Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations 2011 for HDFC Mutual Fund
1 month agoSuccessful closure of US FDA Inspection at Piramal Pharmas manufacturing facility located at Sellersville (USA) facility
1 month agoSuccessful closure of US FDA Inspection at Piramal Pharmas manufacturing facility located at Sellersville (USA) facility
1 month agoNewspaper Advertisement for dispatch of notice of the 6th Annual General Meeting and E-Voting information
2 months agoNewspaper Advertisement for dispatch of notice of the 6th Annual General Meeting and E-Voting information
2 months agoBusiness Responsibility and Sustainability Reporting for the Financial Year 2025-26
2 months agoBusiness Responsibility and Sustainability Reporting for the Financial Year 2025-26
2 months agoNotice of the 6th Annual General Meeting and Annual Report for the financial year 2025-26
2 months agoNotice of the 6th Annual General Meeting and Annual Report for the financial year 2025-26
2 months agoAnnual reports
Concalls & investor presentations
Jul 2026
ConcallPresentation
Apr 2026
ConcallPresentation
Apr 2026
ConcallPresentation
Jan 2026
ConcallPresentation
Jan 2026
ConcallPresentation
Nov 2025
ConcallPresentation
Jul 2025
ConcallPresentation
Jul 2025
ConcallPresentation
May 2025
ConcallPresentation
May 2025
ConcallPresentation
Jan 2025
ConcallPresentation
Jan 2025
ConcallPresentation
Jan 2025
ConcallPresentation
Oct 2024
Jul 2024
May 2024
ConcallPresentation
May 2024
ConcallPresentation
Jan 2024
ConcallPresentation
Jan 2024
ConcallPresentation
Oct 2023
ConcallPresentation
Oct 2023
ConcallPresentation
Aug 2023
ConcallPresentation
Aug 2023
ConcallPresentation
May 2023
ConcallPresentation
May 2023
ConcallPresentation
Feb 2023
ConcallPresentation
Nov 2022
ConcallPresentation
Nov 2022
ConcallPresentation
Corporate Actions
Date
Type
Details
2025-07-16
Dividend
0.14
2024-07-12
Dividend
0.11
2023-08-02
Rights
5:46;81.0 (Rights ratio;Offer price)
Company details
Registered office
Ananta Building, Piramal Corporate Park Opp. Fire Brigade, Kamani Junction L B S Marg Kurla (West) Mumbai Maharashtra PIN: 400070 Tel No: 022 38023000 / 4000 Fax No: 022 22811977 Email: [email protected] Internet: www.piramalpharma.com
Registrars
C 101, 247 Park, LBS Marg, Vikhroli (W), Mumbai(Old Address:) C-13 Pannalal Silk Compound, L B S Marg, Bhandup Mumbai Maharashtra C 101, 247 Park LBS Marg Vikhroli (West) PIN: Tel No: +91 810 811 8484 Fax No: 91-022-49186060 Email: [email protected] Internet: https://in.mpms.mufg.com/
Management
Maneesh Sharma, Company Secretary & Compliance Officer
Nandini Piramal, Chairperson
Peter DeYoung, Whole Time Director
Vivek Valsaraj, Executive Director & Chief Financial Officer
Jairaj Purandare, Non Executive Independent Director
Sridhar Gorthi, Non Executive Independent Director
Peter Stevenson, Non Executive Independent Director
Vibha Paul Rishi, Non Executive Independent Director
Nathalie Leitch, Non Executive Director
Amit Jain, Non Executive Director
Amit Soni, Non Executive Independent Director
Details
BSE 543635
NSE PPLPHARMA
ISIN INE0DK501011